The company, a collaboration between Torrey Pines Investments and a German research institution, is the rare drugmaker in the field forgoing GLP-1s.
A new startup is making a bold move in the world of obesity drug development: It’s not working with the GLP-1 target that has taken the world by storm.
Just a few years ago, the term “GLP-1” would have been a foreign concept to most Americans. Now, i... [599 chars]